CULLINAN PEARL
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations. Cullinan Pearl is a subsidiary of Cullinan Oncology.
CULLINAN PEARL
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cullinanoncology.com
Status:
Active
Total Funding:
0
Investors List
Cullinan Oncology
Cullinan Oncology investment in Series A - Cullinan Pearl
Taiho Ventures
Taiho Ventures investment in Series A - Cullinan Pearl
Official Site Inspections
http://www.cullinanoncology.com
- Host name: 21.104.215.35.bc.googleusercontent.com
- IP address: 35.215.104.21
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Cullinan Pearl"
Cullinan Therapeutics | Modality-Agnostic Targeted …
With patient benefit as our priority, and anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to …See details»
About - Cullinan Therapeutics
We will provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. Furthermore, we actively seek diverse external perspectives from across the industry and …See details»
Cullinan Oncology - Company Profile & Staff Directory - ContactOut
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan …See details»
Leadership - Cullinan Therapeutics
Mary recently served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, a non-profit biotech organization, where she had previously served as the organization’s Chief of …See details»
Cullinan Oncology Company Profile | Management and Employees …
Www.cullinanoncology.com Cullinan Oncology Profile and History Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic …See details»
CULLINAN ONCOLOGY, INC.
4 which they can communicate directly and confidentially with the presiding Director or with the non-management Directors as a group. E. Director Access to Management and Independent …See details»
Cullinan Oncology Management Team | Org Chart - RocketReach
Cullinan Oncology employs 88 employees. The Cullinan Oncology management team includes Nadim Ahmed (President and CEO), Jessica Weinstein (Director, Communications), and …See details»
CULLINAN ONCOLOGY, INC.
3 • Review all Stockholder Nominations and proposals submitted to the Company under the Securities Exchange Act of 1934, as amended, or otherwise, and anySee details»
Cullinan Therapeutics - Crunchbase Company Profile & Funding
Cullinan Therapeutics raised $280 million in a private placement to target the autoimmune market. Additionally, the company announced the appointment of a new Chief Financial Officer.See details»
Cullinan Oncology CEO and Key Executive Team | Craft.co
Cullinan Oncology's President, Chief Executive Officer & Director is Nadim Ahmed. Other executives include Patrick Baeuerle, Scientific Advisory Board Member; Kevin A. Johnston, …See details»
Cullinan Oncology - Craft
Oct 29, 2024 Cullinan Oncology has 4 employees at their 1 location and $18.94 m in annual revenue in FY 2021. See insights on Cullinan Oncology including office locations, competitors, …See details»
Cullinan Oncology: Employee Directory | ZoomInfo.com
Jan 14, 2024 Cullinan Oncology Contact Info: Phone number: (617) 410-4650 Website: www.cullinanoncology.com What does Cullinan Oncology do? Cullinan Oncology is a …See details»
CULLINAN ONCOLOGY, INC.
2 experience or background that results in the individual’s financial sophistication, including being or having been a chief executive officer, principal financial officer or other senior officer withSee details»
Research & Development - Cullinan Therapeutics
At Cullinan, our model is unique: we identify high impact targets and then pursue the best modality to address each identified target, focusing on molecules that inhibit key drivers of …See details»
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive
Oct 18, 2021 Ahmed’s appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition to a later-stage …See details»
Cullinan Oncology - workinbiotech.com
Cullinanoncology.com. linkedin.com . job board . Drug notes: CLN-049 Clin1 AML, MDS; CLN-619 Clin1 oncology; CLN-617 Clin0 oncology; CLN-978 Clin1 B-cell NHL; 2 undisclosed programs …See details»
Cullinan Oncology Announces the Appointment of David P. Ryan, …
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on modality-agnostic …See details»
Cullinan Oncology Completes $131.2 Million Series C Financing
Dec 17, 2020 Matt Burke [email protected] +1 603.315.0618 Release Summary. Cullinan Oncology Completes $131.2 Million Series C Financing. Contacts. Matt Burke …See details»
Programs - Cullinan Therapeutics
We are dedicated to advancing our deep and diversified pipeline to create new standards of care for patients in need of better options. We leverage our scientific excellence to create …See details»
Nadim Ahmed, President and CEO working at Cullinan Oncology
Jul 1, 2023 Website https://www.cullinanoncology.com Company Size * * * * * * * * * * * * Employees 65 profiles available ... Chief Executive Officers are responsible for making sure …See details»